Aditxt, Inc. has announced updates to its merger agreement with Evofem Biosciences, Inc. As per recent amendments, Aditxt will adjust the timing and amounts of its equity investments in Evofem. The Third Parent Equity Investment, originally set at $2 million by September 6, 2024, has been modified to $1.5 million with a new deadline of September 30, 2024. Additionally, the Fourth Parent Equity Investment, initially planned at $1 million by September 30, 2024, has been updated to $1.5 million with a deadline extension to October 31, 2024. These changes follow the merger agreement where Evofem will become a wholly owned subsidiary of Aditxt.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-081146), on August 27, 2025, and is solely responsible for the information contained therein.
Comments